In its upcoming report, TransMedics (TMDX) is predicted by Wall Street analysts to post quarterly earnings of $0.18 per share, reflecting an increase of 50% compared to the same period last year.
Despite a Q3 earnings miss and short-seller allegations, TMDX has shown remarkable five-year growth and operational advantages. TMDX's market share in heart, liver, and lung transplants has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback